title: [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.
abstract: Ten children with stage III or IV neuroblastoma that had either relapsed or was refractory were treated with [131I]-metaiodobenzylguanidine (MIBG) from 1984 to 1986. The total dose ranged from 4,365 to 21,900 MBq and was given in one to five courses. Two patients achieved a complete remission (CR), two, a partial remission (PR), and three, an arrest of the disease. Pharmacological studies showed that 93% of detectable radioactivity was attributable to MIBG at the beginning of the infusion. However, by the end of the infusion this had decreased to 88%. The terminal half-life of MIBG was 37.0 h, whereas that of non-MIBG-bound iodine was 71.6 h. Therefore, the radioactivity-time product of non-MIBG-bound 131I was much higher than that of MIBG. Dosimetric studies showed a mean level of absorbed radiation for the total body of 160 microGy/MBq, a liver irradiation of 540 microGy/MBq and a mean tumour radiation of 10,500 microGy/MBq.
authors.affiliation: Department of Pediatric Hematology/Oncology, Eberhard-Karls University, Tübingen, FRG.
authors.forename: T
authors.initials: T
authors.lastname: Klingebiel
authors.forename: J
authors.initials: J
authors.lastname: Treuner
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: K D
authors.initials: KD
authors.lastname: Keller
authors.forename: R
authors.initials: R
authors.lastname: Dopfer
authors.forename: U
authors.initials: U
authors.lastname: Feine
authors.forename: D
authors.initials: D
authors.lastname: Niethammer
mesh_terms: D019797:3-Iodobenzylguanidine; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004307:Dose-Response Relationship, Radiation; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000473:pathology / Q000532:radiotherapy*; D012074:Remission Induction; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine